Nexalin Technology (NXL) Cash from Financing Activities (2021 - 2026)
Nexalin Technology's quarterly Cash from Financing Activities came in at $756421.0 in Q1 2026, up 44.48% quarter-over-quarter from $523550.0 in Q4 2025.
Nexalin Technology has reported Cash from Financing Activities for 5 years, with the latest figure at $756421.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $756421.0; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (changed N/A YoY), and the FY2025 full-year result was $5.2 million, up 14.48% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $756421.0, up from $523550.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $8.5 million in Q3 2022, with the low at -$200000.0 in Q1 2023.
- Average Cash from Financing Activities over 4 years is $1.6 million, with a median of $261825.0 recorded in 2022.
- Peak annual rise in Cash from Financing Activities reached 200100.0% in 2023, while the deepest fall reached 200100.0% in 2023.
- Tracing NXL's Cash from Financing Activities over 4 years: stood at $8.5 million in 2022, then plunged by 102.35% to -$200000.0 in 2023, then soared by 361.78% to $523550.0 in 2025, then jumped by 44.48% to $756421.0 in 2026.
- The last three Cash from Financing Activities figures came in at $756421.0 (Q1 2026), $523550.0 (Q4 2025), and -$200000.0 (Q1 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.09 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -26.93 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | -25.00 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -97.90 Mn |
| 10 | Nexalin Technology | 11.19 Mn | 8.48 Mn | 13,133.00 | 756,421.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 756,421.00 |
| Mar 31, 2026 | 756,421.00 |
| Dec 31, 2025 | 523,550.00 |
| Dec 31, 2025 | 523,550.00 |
| Mar 31, 2023 | -200,000.00 |
| Mar 31, 2023 | -200,000.00 |
| Sep 30, 2022 | 8.52 Mn |
| Sep 30, 2022 | 8.52 Mn |
| Jun 30, 2022 | -5,000.00 |
| Jun 30, 2022 | -5,000.00 |
| Mar 31, 2022 | 100.00 |
| Mar 31, 2022 | 100.00 |
| Dec 31, 2021 | 934,443.00 |
| Dec 31, 2021 | 934,443.00 |